MedTrace Logo

Safety Study of Rituximab (Rituxan®) in Chronic Urticaria

NCT00216762 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2015-09-02

No results posted yet for this study

Summary

This study is being done to find out if a drug called Rituxan (Rituximab) is safe and effective in treating people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.

Conditions

  • Urticaria

Interventions

DRUG

Rituximab

Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart

Sponsors & Collaborators

Principal Investigators

  • Clifton O. Bingham, III, MD · Johns Hopkins University, Divisions of Rheumatology and Allergy and Clinical Immunology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00216762 on ClinicalTrials.gov